Skip to Content
Merck
CN
  • Design, synthesis, single-crystal and preliminary antitumor activity of novel arenesulfonylimidazolidin-2-ones.

Design, synthesis, single-crystal and preliminary antitumor activity of novel arenesulfonylimidazolidin-2-ones.

Bioorganic & medicinal chemistry letters (2012-02-10)
Alaa A-M Abdel-Aziz, Adel S El-Azab, Hussein I El-Subbagh, Abdulrahman M Al-Obaid, Amer M Alanazi, Mohamed A Al-Omar
ABSTRACT

Novel series of 1-(arenesulfonyl)imidazolidin-2-one (3a-i) and 1,3-bis(arenesulfonyl)imidazolidin-2-one (5a-i) have been synthesized and tested for their antitumor activity against 60 tumor cell lines taken from nine different organs. A significant inhibition for cancer cells was observed with series 5a-i compounds compared with the series 3a-i which showed a weak inhibition. Compounds 5a-i showed good inhibitory effect at the lung cancer HOP-92 and renal cancer CAKI-1 and UO-31 cell lines. Compound 5e showed remarkable broad-spectrum antitumor activity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Imidazolidone, 96%